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An effective immune response against viral infections depends on the activation of cyto-
toxicT cells that can clear infection by killing virus-infected cells. Proper activation of these
T cells depends on professional antigen-presenting cells, such as dendritic cells (DCs). In
this review, we will discuss the potential of peptide-based vaccines for prevention and
treatment of viral diseases. We will describe features of an effective response against both
acute and chronic infections, such as an appropriate magnitude, breadth, and quality and
discuss requirements for inducing such an effective antiviral immune response. We will
address modifications that affect presentation of vaccine components by DCs, including
choice of antigen, adjuvants, and formulation. Furthermore, we will describe differences
in design between preventive and therapeutic peptide-based vaccines. The ultimate goal
in the design of preventive vaccines is to develop a universal vaccine that cross-protects
against multiple strains of the virus. For therapeutic vaccines, cross-protection is of less
importance, but enhancing existingT cell responses is essential. Although peptide vaccina-
tion is successful in inducing responses in human papillomavirus (HPV) infected patients,
there are still several challenges such as choosing the right target epitopes, choosing
safe adjuvants that improve immunogenicity of these epitopes, and steering the immune
response in the desired direction. We will conclude with an overview of the current status
of peptide vaccination, hurdles to overcome, and prospects for the future.
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INTRODUCTION
Viruses are small infectious agents that consist of nucleic acid
that is coated in a simple protein shell or a cell-membrane-
like protein casing, and need to infect host cells to replicate
(1). Viruses can cause acute and chronic infections. In acute
virus infections, such as a common cold, the virus is typically
cleared from the body within a week. However, in some cases,
an acute infection is followed by persistence of the virus in the
host. Herpes simplex virus is an example of a virus causing a
persistent infection, due to ability of the virus to hide in neu-
rons. Often, these types of persistent infections do not cause any
symptoms in healthy hosts (2). Chronic infections are a type
of persistent infection often caused by an inefficient immune
response of the host, leading to long-lasting symptoms. Espe-
cially, acute and chronic virus infections have a major general
health impact. Annual influenza epidemics, for instance, result
in about 3–5 million cases of severe illness and approximately
250,000–500,000 deaths worldwide (3). An example of a chronic
infection causing major health impact is Human Immunodefi-
ciency Virus (HIV). In 2012, more than 35 million people were
living with an HIV infection and 1.6 million people died from
an AIDS-related illness (4). Some persistent virus infections,
such as Epstein–Barr virus (EBV) and Human Papillomavirus
(HPV) can lead, under certain conditions, to the development
of tumors (5, 6). Because viruses have such a major impact on
health, strategies to limit or prevent virus infections are of major
importance.
Mammals have developed a refined immune system to cope
with all kinds of infections. Especially, the adaptive arm of the
immune response is important in limiting and clearing viral
infections. The humoral immune response consists of antibodies
specific for the virus that can capture and neutralize virus particles
before they enter the cell. However, if these antibodies are ineffec-
tive, viruses are able to infect host cells and can only be cleared by
the cellular arm of the immune response. Once a virus infects a
cell, the virus will use the protein-synthesis machinery of the host
cell to synthesize its own proteins. During this process, some of
the newly synthesized proteins will be degraded into peptide frag-
ments and, if they have sufficient binding affinity, bind to MHC
class I molecules. These MHC class I-peptide complexes will then
be presented on the cell surface of an infected cell and activated
CD8+ T cells, specific for the peptide, can recognize the MHC
class I-peptide complex and induce apoptosis of the infected cell
by releasing cytotoxic granules. Activation of these CD8+ T cells
occurs in the draining lymph nodes,where antigen-presenting cells
(APCs), such as dendritic cells (DCs), and naïve T cells encounter
each other. In these lymph nodes, DCs and CD4+ T cells pro-
vide the co-stimulation necessary for proper activation of CD8+
T cells. This process is summarized in Figure 1 and will be further
discussed in the next paragraphs.
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FIGURE 1 | Routes of presentation of viral peptides on DCs. Viruses can
enter cells by two ways: some viruses can infect cells directly, leading to
replication of virus inside the cells. During this process, some of the viral
proteins will be degraded into peptide fragments, which will be presented on
MHC class I molecules to CD8+ T cells (I). APCs, such as DCs can also take
up viral particles or remnants of virally infected cells (II). During processing by
professional APCs, viral peptides can be presented on MHC class I molecules
via the cross-presentation pathway (III). In parallel, these extracellular-derived
peptides will be presented on MHC class II molecules. The TCR of
virus-specific CD4+ T can recognize MHC class II-peptide complexes on
professional APCs. Next to the interaction of the MHC class II-peptide
complex with the TCR, CD4+ T cells can activate DCs by interaction of CD40
with CD40 ligand on the DC (IV). This interaction activates DCs and results in
upregulation of maturation markers CD80/CD86. CD80 and CD86 interact
with CD28 on naïve CD8+ T cells (V). Together with the recognition of the
MHC class I-peptide complex by the TCR, CD28 signaling will result in the
activation of the CD8+ T cell (VI). These activated CD8+ T cells will differentiate
into effector T cells that can recognize the MHC class I-peptide complex on
virally infected cells. Binding of the TCR to the MHC class I-peptide complex
leads to activation of the CD8+ T cell and the release of cytotoxic granules
containing perforins and granzymes, and the production of cytokines such as
TNF-α and IFN-γ (VII).
During the initial phase of a viral infection, there is a significant
increase in the number of CD8+ T cells. Priming of these naïve T
cells will not only occur through the classical pathway via infec-
tion of a cell, directly leading to presentation of peptides on MHC
class I molecules, but also through cross-presentation. Cross-
presentation enables the presentation of viral peptides, taken up
from extracellular sources, on MHC class I molecules. Several dif-
ferent cell types have been demonstrated to cross-present antigens
in vivo, including professional APCs such as macrophages and DCs
(7). CD8+ T cells, activated either through the classical or cross-
presentation pathway, induce apoptosis of virus-infected cells by
the release of cytotoxic granules and the production of TNF-α and
IFN-γ as depicted in Figure 1. The cytotoxic granules contain
perforins, granzymes, and granulysin. Perforins aid in deliver-
ing contents of granules into the cytoplasm of the target cell.
Granzymes, such as granzyme B, and granulysin activate apoptosis
of the target cell. TNF-α can interact with the TNFR-I receptor,
which induces apoptosis of infected cells. IFN-γ is an important
cytokine in the immune response to various viral infections, since
it can induce an antiviral state in uninfected cells and enhance the
cytotoxic function of CD8+ T cells. By the classical antigen pre-
sentation pathway or by the cross-presentation pathway, any form
of virus can be presented on MHC class I and MHC class II and
thereby stimulate antiviral responses by both CD8+ T cells and
CD4+ T cells, respectively, leading to a broad cellular response to
infection (8). After infection, some of these activated T cells will
develop into memory T cells. In the event that a secondary infec-
tion occurs, these cells can rapidly mature into effector cells and
respond to infection.
Antigen-presenting cells that reside at the site of infection, can
take up viral particles or remnants of virally infected cells from
extracellular sources, and present them on MHC class II mol-
ecules. Subsequently, CD4+ T cells recognizing peptides in the
context of MHC class II will be activated. These activated CD4+
T cells are capable of producing a wide range of cytokines and
chemokines and can even exert cytotoxic functions themselves.
Based on cytokine production, CD4+ T cells can be divided into
several subsets, the most classical being Th1, Th2, and Tregs. Th1
cells are generally characterized by the production of IFN-γ. Th2
cells, on the other hand, produce mainly IL-4, IL-5, and IL-13
and are important for providing an immune response against
helminths by activating eosinophils, basophils, mast cells, and B
cells. The third classical subset are the Treg cells, which are char-
acterized by the production of IL-10 and TGF-b, and have mainly
regulatory tasks such as dampening effector functions and limiting
immunopathology (8, 9). In addition to their effector functions,
activated CD4+ T cells can provide help to CD8+ T cells by CD40-
CD40L interaction, which induces up regulation of ligands, such
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as CD80 and CD86, on DCs. These ligands interact with CD28 on
naïve T cells, providing a co-stimulatory signal to activate CD8+
T cells (10). The mechanism by which CD4+ T cells can provide
help to CD8+ T cells is shown in Figure 1.
In this review, we will discuss the value of T cell responses in
both acute and chronic viral infections and how knowledge of
these responses can help in designing effective vaccines.
Currently, antiviral drugs are the main treatment option to
combat viral diseases. However, antiviral treatment is associated
with side effects and resistance through viral escape. Making use
of the hosts own immune defense system by vaccination would
be another powerful approach to combat viral diseases. However,
many vaccination strategies are based on antibody-mediated pro-
tection and are only partially successful. Antibodies can be very
efficient in preventing virus infection, but due to the variability of
many virus surface proteins, the virus can escape and infect host
cells. Once a virus has entered a cell, infection can only be cleared
by a cellular response. We will highlight the history of synthetic
T cell based vaccines as an important strategy to induce T cell
responses and discuss current developments in this field. Then,
we will discuss how the design of these vaccines, such as choice of
antigen and adjuvant, influences their efficacy. Finally, we will con-
clude with potential pitfalls and recommendations for the design
of effective peptide vaccines against virus infections.
T CELL RESPONSES IN VIRAL INFECTIONS
There are many viruses for which T cells, both CD8+ and CD4+,
have been shown to play a role in protection, such as measles virus,
cytomegalovirus (CMV), hepatitis C virus (HCV), and HIV (11–
14). In general, an efficient antiviral adaptive response is thought
to be of the Th1 type (15). However, many viruses can inhibit
this Th1 response by downregulating the production of interfer-
ons (16, 17). This type of manipulation of the immune response
can greatly influence the outcome of the infection. In infections
caused by hepatitis viruses, manipulation of the immune response
by the virus can lead to a persistent infection, in which the host is
incapable of clearing the virus from the body. In mice, lympho-
cytic choriomeningitis virus (LCMV) is used as a model to study
the role of CD8+ and CD4+ T cells in both acute and chronic
infections. CD8+ T cell-deficient mice, which were infected with a
LCMV-strain that normally causes acute virus infection, were not
able to control infection and developed a persistent infection. In
mice depleted of CD4+ T cells, infection with murine LCMV led
to chronic infection, even in the presence of CD8+ T cells. This
model shows that in acute infection, CD8+ T cells are sufficient to
clear infection, but the help of CD4+ T cells is required (18).
The importance of T cell responses during acute viral infec-
tions in humans can be illustrated by research from Sridhar et al.
describing that individuals with higher numbers of pre-existing
CD8+ T cells specific for conserved CD8 epitopes, developed less
severe illness after infection with pandemic H1N1 influenza virus
(19). That not only CD8+ T cells mediate protection to influenza
challenge, has been shown in a unique human challenge study by
Wilkinson et al. In this study, healthy volunteers were challenged
with influenza A virus, and antibody and T cell responses against
influenza before and during infection were monitored. They
showed that, in the absence of antibody responses, pre-existing
CD4+ T cells responding to influenza internal proteins were asso-
ciated with less severe illness and lower virus shedding. Further
characterization of these CD4+ T cells showed that these cells had
a cytotoxic function (20). These studies describe the importance
of both CD8+ and CD4+ T cells in the immune response against
influenza virus.
During chronic viral infections, when the host is not able to
clear the virus, the main role of cytotoxic T cells is to limit dis-
ease severity and delay disease progression. This is exemplified by
studies on HIV infection. Early during infection with HIV, there
is a decline in viral replication as measured by the number of HIV
RNA copies in plasma samples (21). In the first stages of HIV
infection, it has been shown that patients with higher numbers of
memory cytotoxic T cells show a much lower viral load in plasma
than patients with a lower number of memory cytotoxic T cells,
indicating that this decline is mediated by cytotoxic CD4+ T cells
(22). In addition, cytotoxic CD4+ T cells are an immunological
predictor of disease outcome. Patients that controlled HIV replica-
tion without antiretroviral therapy showed an increased number
of CD4+ T cells specific for HIV proteins (23). The importance
of CD8+ T cells in delaying HIV disease progression is shown in
studies where a loss of CD8+ T cells coincides with disease pro-
gression (24, 25). Findings that HIV escape mutations often occur
at HLA-binding sites specific for CD8 epitopes, the strong asso-
ciation of certain HLA-alleles with protection from HIV disease
progression, the temporal relationship between viral load decline
and increase in specific CD8+ T cells, and CD8+ T cell depletion
studies in simian models, underline the importance of CD8+ T
cell responses (11, 26–29). Knowledge on the mechanism of pro-
tection of T cell responses in immunity against viruses can be
helpful in designing preventive and therapeutic therapies, such as
vaccination.
HISTORY OF PEPTIDE VACCINATION
Many vaccines against virus infections are based on inducing
antibody responses, consequently, these vaccines are often poor
inducers of T cell responses (30). Since T cells are important in
protection against many viral infections, there is a need for T cell
inducing vaccines. By including small protein fragments (pep-
tides), in a vaccine, which can be presented by MHC-molecules
to CD4+ and CD8+ T cells, specific T cell responses can be
induced. In Table 1, characteristics of two of the classical pre-
ventive vaccines for viral infections, i.e., protein vaccines and
live attenuated vaccines, are compared to peptide vaccines. The
main advantage of peptide vaccines over classical vaccines is that
it is possible to specifically induce T cell responses and that the
production process of these vaccines is relatively easy. The first
synthetic peptide vaccine able to induce a T cell response in mice
was published by Aichele et al. This vaccine contained a 15-mer
peptide, derived from the NP protein of LCMV, suspended in
incomplete Freund’s adjuvant (IFA) (31). Further experiments
showed that these peptide vaccines were able to render a cer-
tain amount of protection against challenge with virus (32, 33).
These results were promising, but in later studies where mice were
vaccinated with 15-mer CTL epitopes derived from adenovirus
type 5 early region (Ad5E1) oncogenes in combination with
IFA, an enhanced outgrowth of tumors was observed following
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Table 1 | Comparison of classical protein vaccination, live attenuated vaccination, and peptide vaccination.
Classical protein vaccine Live attenuated vaccine Peptide vaccine
Composition Inactivated split virion or purified
subunit
Attenuated virus, capable of replication Synthetic, small protein
fragments
Humoral response Yes, induces humoral response Yes, mimics natural infection Possible, depends on
peptides included
CD4 response No Yes Yes
CD8 response No Yes Yes
Preexisting response Not important Important, Ab can capture vaccine Not important
Adjuvant Required for cellular response Not required Required
Production Biological Biological Synthetic
Safety Risk of contamination with extraneous
agents and proteins of the production
substrate
Risk of contamination with extraneous
agents and proteins of the production
substrate
Well controlled and
highly pure production
process
Flexibility to match escape variants Not easy Not easy Easy
Target conserved components No, primarily strain-specific response To some extent, limited cross-reactivity Yes, capable of inducing
a broad response
Protein vaccines are a form of inactivated vaccines that consist of purified subunit or subvirion products. Live attenuated vaccines are attenuated viruses, derived from
disease-causing virus. These attenuated viruses still replicate in the host, but do not cause disease. Peptide vaccines are completely synthetic vaccines, comprised
of small protein fragments.
vaccination (34). In hindsight, this observation might not be
that surprising. Only peptides of 20 amino acids or longer will
need to be degraded by proteolytic enzymes and are therefore
presented exclusively by professional APCs, thereby ensuring suf-
ficient co-stimulation. Shorter peptides can be directly loaded on
any MHC molecule, also on non-professional APCs, which may
lead to the induction of tolerance. Additional research showed
that indeed the problem with the 15-mer adenovirus peptides
was induction of tolerance, since they were presented by non-
professional APCs lacking appropriate co-stimulation, resulting
in suboptimal presentation of the peptide. When mice were vacci-
nated with peptide-loaded DCs, there was an anti-tumor response
and no tolerance induction, showing that presentation of these
peptides on professional APCs can be effective without induction
of tolerance (35).
PEPTIDE LENGTH
Thus, the first advantage of peptides of 20 amino acids or longer,
which are considered as long peptides, is that they require pro-
cessing of these peptides by professional APCs, thereby reducing
the chance of inducing tolerance by peptide vaccination (36). Fur-
thermore, they may contain multiple epitopes specific for different
MHC-molecules. Thereby, broadening the potential response in
both the individual and at population level (37). Another advan-
tage of using long peptides is that, next to CD8 epitopes, this type
of peptide often contains CD4 epitopes. These CD4 epitopes pro-
vide co-stimulation during priming of CD8+ T cells and promote
memory CD8+ T cells (38, 39). One year after the first successful
immunization of mice with a free synthetic LCMV peptide, Fay-
olle et al. described that this 15-mer peptide not only contained
a CD8 epitope but also a CD4 epitope (40). This discovery con-
firms the valuable contribution of co-stimulation in a vaccine.
In addition to considering the importance of the length of the
peptide, other characteristics are equally or even more impor-
tant. Therefore, considerations for the choice of antigen will be
discussed next.
CHOICE OF ANTIGEN
Aspects hampering the design of an effective preventive strategy
for virus infections are that these viruses have, besides great genetic
diversity, also developed multiple mechanisms to evade the host’s
immune response (41, 42). A promising approach is to direct the
immune response to conserved parts of the virus, which do not
allow for mutations. Virtually all viruses contain certain proteins
or peptides that are highly conserved. Indeed, for HIV, the Gag
protein appears to be a good candidate for use as a T cell vaccine
component. The Gag protein is highly conserved, and although it
is a late structural protein, Sacha et al. showed in a simian model
that CD8+ T cells recognize Gag-derived epitopes as early as 2 h
post infection. This fast processing and presentation is thought to
be necessary for early clearance of the virus (43). In an ex vivo
study on PBMCs of HIV-infected individuals, vigorous CD8+ T
cell responses to Gag epitopes were observed and the breadth of the
CD8+ T cells specific for conserved Gag epitopes inversely corre-
lated with viremia (44). A screening in patients with both acute and
chronic HCV infection showed that specific T cell responses were
found against conserved parts of the virus. Immunogenic regions
were identified within core, NS3 and NS4 proteins (45). Influenza
virus also contains good candidate proteins, such as nucleopro-
tein (NP), which is a major target of T cell responses (46). These
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studies show that there are T cells available directed toward con-
served parts of the virus. Knowledge of these parts can be used in
the design of a T cell inducing vaccine.
Since the introduction of sequence analysis tools, it is relatively
easy to determine whether a certain peptide sequence is conserved.
However, a high level of conservation is not the only require-
ment for a peptide vaccine to be effective. The peptide will have
to be processed by the proteasome and then bind to the MHC
molecule. Bio-informatic tools can be helpful to predict, which
sequences may be immunogenic for T cells. These tools can pre-
dict which sequences will bind to MHC, based on preferred amino
acids of peptide anchor binding positions of these molecules. Fur-
thermore, tools are available that predict which sequences will be
processed by the proteasome and by TAP (transporter associated
with antigen processing) transport (47). Together, these tools pro-
vide means of selecting a number of possible conserved T cell
epitopes. Schellens et al. showed in PBMCs of HIV-infected indi-
viduals that indeed these bio-informatics tools are valuable for
predicting novel T cell epitopes (48).
Another important requirement for inducing T cell responses
is that there are T cells available that can recognize the peptide. Tan
et al. described the importance of the availability of naïve epitope-
specific CD8+ T cells in the host prior to infection and showed that
precursor frequencies are indeed a good predictor for responses
observed after infection, since a higher number of epitope-specific
CD8+ T cells led to an increased T cell response after infection
(49). Next to precursor frequencies, binding affinity of peptides to
MHC is also a predictor of immunogenicity as has been shown in
peripheral blood lymphocytes of acute HBV patients (50). Some
groups have shown that it is possible to enhance peptides by
increasing binding affinity of the peptide to the MHC molecule
(51, 52). These enhanced peptides might induce a T cell response
to conserved, but otherwise too low affinity epitopes. Another
important consideration when vaccinating with short peptides is
HLA-specificity. Since peptides of 8–11 amino acids long bind
directly into the MHC class I binding groove the peptide has to
match the HLA type of the vaccinated individual. To overcome the
need for individualized vaccination, Tan et al. selected short epi-
topes with the capacity to bind to multiple HLA-alleles. HLA-A2
transgenic mice vaccinated with this multi-HLA peptide vaccine,
showed a reduction of virus in the lungs and increased survival fol-
lowing influenza infection, compared with mock vaccinated mice,
showing that vaccination with peptides can positively influence
disease outcome (53).
Presentation of peptides by APCs greatly depends on the form
in which they are offered to APCs. Zhang et al. compared intact
proteins and long peptides in the cross-presentation pathway and
showed that long peptides traffic to both the endosomes and the
cytosol, whereas whole protein was found to traffic only to the
endosomal compartments. Therefore, whole proteins could not
be processed through the cross-presentation pathway. This differ-
ence in processing led to a CD4+ T cell restricted response after
immunization with protein, while immunization with peptides
also led to a CD8+ T cell response (54). Rosalia et al. compared
whole protein processing to processing of long peptides, both in
mouse and in human DCs. Soluble protein antigen ended up
mostly in the endolysosomes, while long peptides seemed to be
more efficiently internalized by DCs leading to a faster intracellu-
lar routing. Therefore, long peptide vaccination ultimately leads to
enhanced CD8+ T cell activation compared to whole protein (55).
In line with these findings, recent research on peptide vaccination
is mainly directed to improving antigen presentation of the pep-
tides of choice,by choosing the right form in which the peptides are
presented. Rosario et al. used an HIV-synthetic long peptide vac-
cine to boost HIV-specific T cell responses in a macaque model and
showed that boosting with these synthetic long peptides primarily
increased the breadth of the CD4+ T cell responses (56).
FEATURES OF AN EFFECTIVE RESPONSE
To induce an effective response against viral infections, there are
several requirements that should be met. One important require-
ment is that there is a sufficient number of T cells available to
kill virus-infected cells. The need for an appropriate magnitude
of T cells in order to clear virus was elegantly shown by Thimme
et al. in a CD8+ T cell depletion study in chimpanzees. Chim-
panzees were depleted of CD8+ T cells, and subsequently infected
with HBV, complete depletion of CD8+ T cells in the chimpanzees
resulted in the inability to clear virus. When CD8+ T cells reap-
peared in the animal, 98% of viral DNA was eliminated from the
liver. However, while the number of CD8+ T cells remained sup-
pressed, the animal was not able to clear virus completely. Only
when the number of CD8+ T cells was able to expand further, the
virus was completely eliminated (57). Furthermore, an increased
breadth of T cell responses can be beneficial. Analysis of CD8+ T
cell responses in untreated HIV-infected individuals showed that
an increasing breadth of Gag-specific responses is associated with
decreased viremia (58). In parallel with these findings, vaccination
of mice with a vaccine containing multiple epitopes, were more
effective in generating a response to influenza infection than vac-
cination with single epitopes (49). These findings indicate that a
broad response is more effective than a response dedicated to only
one peptide. Another advantage of induction of a broad response
is that small mutations of the virus will not lead to escape of
the virus from the immune response. Next to a broad response,
T cell responses of high avidity also contribute to an antiviral
response. Ex vivo screening of T cell responses in HIV-infected
patients showed that controllers reacted to lower antigen concen-
trations compared to non-controllers, indicating that controllers
have T cell responses of higher functional avidity and that this
higher avidity is advantageous (59).
A fourth requirement is that an effective antiviral response
should be of proper functionality to enable control or clearance of
the virus. CD8+ T cells are the main cell type that is involved in
clearance of viral infections. These cells are characterized by the
production of Th1-cytokines such as IFN-γ and by the expression
of degranulation marker CD107a (60). CD107a is an indicator
of cytotoxic functions such as the production of granzymes and
perforins. IFN-γ increases expression of both MHC class I and
II molecules and enhances the antigen-presenting function of
MHC class I by stimulating loading of peptides onto this molecule.
Thereby, IFN-γ can induce the cytotoxic function of CD8+ T cells
and promote the production of other cytokines such as TNF-α,
IL-2, and type I interferons. TNF-α induces apoptosis of virus-
infected cells and IL-2 is an important growth factor for T cells.
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Type I interferons, such as IFN-α and IFN-β, can induce resis-
tance to viral infections in uninfected cells, increase MHC class
I expression and antigen presentation and activate both DCs and
macrophages (8, 61). Activated macrophages in their turn produce
chemokines such as MIP-1β to attract more T cells. Together, these
cytokines, chemokines, granzymes, and perforins enable control
or clearance of the virus from the host. In HIV infection, a poly-
functional CD8+ T cell response is observed in non-progressors,
while progressors show a more limited response (62). As reviewed
by Seder et al., a polyfunctional response, characterized by pro-
duction of IFN-γ, TNF-α, and IL-2, was indeed shown to induce
more robust T cell proliferation and protection against several
viral infections (63).
However, elevated amounts of inflammatory cytokines can also
lead to immunopathology as has been shown in H5N1 influenza A
virus infection (64). The immune system normally has its own reg-
ulatory mechanisms, such as the production of anti-inflammatory
cytokines including IL-10 and TGF-β. IL-10 is produced by a wide
range of cells, including T cells, macrophages and neutrophils.
The main function of IL-10 is to act as a negative feedback loop
to suppress the production of IFN-γ and other pro-inflammatory
cytokines (65). TGF-β acts by inducing apoptosis of CD8+ T cells,
which regulates T cell homeostasis and prevents immune inflam-
mation (66). These feedback loops are a way of the immune system
to regulate itself, however viral factors can negatively impact this
balance as is illustrated in HCV infection. Patients with progres-
sive liver injury showed upregulation of Th1-cytokines IFN-γ
and IL-2 and down regulation of the regulatory cytokine IL-
10 (67). Another regulatory mechanism is the upregulation of
inhibitory receptors such as PD-1, LAG-3, and CTLA-4, which
leads to decreased activation potential of T cells and the activa-
tion of inhibitory genes in T cells (68). However, upregulation
of these receptors has also been shown to be responsible for
the exhaustion of T cells and thereby a diminished response in
chronic viral infections (69). Summarizing, an effective antiviral
response consists of a broad variety of antigen-specific T cells of
sufficient magnitude, affinity, and appropriate polyfunctionality.
Furthermore, these T cells should be capable of performing cyto-
toxic functions, but should not induce immunopathology. Such a
response greatly depends on the way antigen is presented to the
T cells, emphasizing the important role APCs play in antiviral
responses.
CO-STIMULATION AND PEPTIDE VACCINATION
In recent years, multiple strategies were developed to increase the
quality of antigen presentation of peptides. One of the strategies,
already described above, is the addition of CD4 help. Long pep-
tides often contain CD4 epitopes that can provide co-stimulation
for CD8+ T cells. However, more general CD4 helper peptides
are available. One example is the non-natural pan HLA-DR bind-
ing peptide (PADRE), which is engineered by introducing anchor
residues for different DR motifs within a polyalanine backbone.
This peptide binds with high or intermediate affinity to the most
common HLA-DR types, and allows it to activate a wide range
of CD4+ T cells (70). The addition of PADRE epitopes is used,
for example, in Dengue virus and HBV virus vaccine develop-
ment, showing promising results in vivo (71, 72). Another group
of universal T helper epitopes are natural tetanus sequences, which
are very promiscuous in their capacity to bind to MHC class II,
and thereby very efficient in acting as a co-stimulus (73). These
universal T helper epitopes can be fused to CD8+ T cell epitopes,
eliciting good immunogenicity, as shown for CMV by La Rosa et al.
(74). However, it remains under debate whether CD4 help should
be antigen-specific or is otherwise not able to stimulate proper
CD8+ T cell responses. A study in which mice were vaccinated
with either non-specific CD4 help or antigen-specific CD4 help,
showed that memory CD8+ T cells can only be efficiently activated
by antigen-specific CD4 help, while effector CD8+ T cells can be
activated by non-specific CD4 help (75).
An important factor in CD4+ T cell help in short peptide vacci-
nation appears to be CD40-CD40 ligand interaction (76). Ligation
of CD40 to CD40 ligand can trigger the production of high levels
of IL-12 by DCs. IL-12 induces Th1-mediated immune responses
and inhibits Th2-mediated responses (77). Furthermore, CD40
ligand stimulates up regulation of ICAM-1, CD80, and CD86 mol-
ecules on DCs. By these mechanisms, DCs can trigger proliferative
responses and IFN-γ production by T cells (78). By adding CD40
ligand as a co-stimulatory molecule, DCs can be activated through
CD40 and in their turn, DCs are able to activate CD4+ T cells and
CD8+ T cells (79).
Another way to activate APCs is by targeting their Toll-like
receptors (TLRs). TLRs are pathogen recognition receptors (PRR)
that recognize molecules shared by pathogens, for example, double
stranded RNA in certain viruses. Activation of these TLRs can then
lead to the production of inflammatory cytokines. By covalently
coupling TLR-activating lipids to the peptide, resulting in so-called
lipopeptides, self-adjuvanting peptides are created. These lipopep-
tides can target the vaccine by activating the TLRs on the required
APCs and the peptides can then be internalized and presented
on MHC-molecules. Thereby, lipopeptides can signal through the
TLRs to induce DC maturation, leading to enhanced antigen pre-
sentation. Jackson et al. designed a synthetic vaccine composed of
a CD4 T helper epitope, a CD8 target epitope, and the lipid moi-
ety Pam2Cys that provided TLR2 targeting, which could induce
DC maturation and antibody and CTL responses (80). Chua et al.
used the TLR2 agonist Pam2Cys to enhance the immunogenicity
of their virus-like particles, containing HCV structural proteins.
The addition of lipopeptide resulted in increased DC maturation
at low doses of the vaccine (81). Indeed, lipopeptide vaccination
can induce protective CTL responses, as shown by Day et al. in a
mouse influenza virus challenge model (82).
ADJUVANTS IN PEPTIDE VACCINATION
To improve the effectiveness of peptide vaccines, there are several
types of adjuvants available, with different effector mechanisms.
Some adjuvants induce depot formation; others directly stimulate
the immune response through additional signals. In earlier work
on peptide vaccination, strong adjuvants were necessary for induc-
tion of immunogenicity. A commonly used adjuvant for peptide
vaccination is IFA, which was applied in the first peptide vaccine,
or the human equivalent Montanide. These water in oil formula-
tions form a depot at the site of injection, leading to “leakage” of
antigen into the body (37, 83). Research by den Boer et al. showed
that the short Ad5E1 peptide still leaks from the IFA depot at day
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200 (84). This depot of antigen and adjuvant can lead to chronic
inflammation of the site of injection that may persist for a long
time. Harris et al. showed that repeated vaccination can even lead
to a site suggestive of a new lymphoid structure, including the
association of mature DCs with proliferating T cells in perivascu-
lar dermal aggregates (85). However, the risk with such depots is
that the peptide might be present for a long time after vaccination,
but the adjuvant might not be, allowing presentation of the peptide
without the necessary co-stimulation and with the risk of induc-
ing tolerance (86). Furthermore, although effective in therapeutic
vaccination, IFA does lead to the formation of lesions on the site
of injection, making it less attractive for use in a preventive vac-
cine (87). Two clinical trials, one with HIV peptides and another
with malaria surface proteins mixed in Montanide, have even been
terminated because of these severe adverse events (88, 89).
An alternative for water in oil formulations could be the use of
vesicular delivery systems. Depending on the nature of the deliv-
ery system, they provide the possibility to incorporate immune
modulators to direct the immune response, protect against degra-
dation of the peptide, directly target the antigen to the place of
interest and, finally, actively transport the antigen across the target
membrane. Currently, there are several delivery systems available
for peptide vaccination, i.e., liposomes, virosomes, virus-like parti-
cles, ISCOMs, and nanoparticles (90). Liposomes consist of a lipid
bilayer, in which antigens or other substances can be entrapped in
the lumen or the lipid bilayer, depending on traits of the peptide.
The lipid bilayer of liposomes can fuse with other bilayers, such as
a cell membrane. Thereby, liposomes can deliver antigens to the
cytosol of APCs (91). Liposomes, containing a short CD8 lipopep-
tide in combination with CpG, were able to induce protection in a
murine influenza challenge model (92). However, liposomes can-
not induce maturation of DCs without addition of an adjuvant and
are therefore not sufficient to induce co-stimulation. To address
this problem, several groups are developing modified liposomes to
increase targeting to DCs by adding targets for C-type lectin recep-
tors such as glycans or mannose, which are typically expressed
on DCs (93). Virosomes, or influenza derived virus-like parti-
cles, have similar membrane-fusion capacities as live influenza
virus, which allows them to actively fuse with cell membranes and
thereby deliver antigens directly into the cytosol of APCs leading to
cross-presentation of antigenic peptides (94). Furthermore, they
have been shown to induce up regulation of maturation markers
on bone marrow-derived DCs, in mouse models (95, 96). How-
ever, as of now, DC maturation capabilities of virosomes have not
been shown in human systems. Thus, liposomes, virosomes, and
other delivery systems can successfully be used to deliver antigens
to the place of interest. In addition, they can provide the necessary
co-stimulation for APCs, either due to their own properties or by
adding other adjuvants to the formulation.
CURRENT PROGRESS IN PEPTIDE VACCINATION
The first and most successful, peptide-based vaccine that is cur-
rently licensed is a therapeutic vaccine against HPV. This vaccine
contains long synthetic peptides directed against viral oncopro-
teins, mixed in Montanide, which induces vaccine-specific CD4+
and CD8+ T cell responses in all patients (87). Since the success of
this therapeutic cancer vaccine, many groups are exploring peptide
vaccination for other viral agents. Therapeutic vaccination, with
synthetic peptides, of HCV patients not responding to standard
treatment, resulted in a decrease in viral RNA as shown in two
separate studies. Klade et al. performed a Phase II clinical study in
HCV patients with their IC41 vaccine, consisting of five synthetic
peptides formulated with a Th1 type adjuvant, poly-I-arginine.
All patients that were vaccinated intradermally with TLR7 agonist
imiquimod as adjuvant, showed a modest decline in viral titers
(97). The study by El-Awady et al., in which HCV patients were
vaccinated with a peptide vaccine consisting of three envelope pro-
teins, showed that in two thirds of the patients both antibody and
T cell responses were detectable resulting in decreased viral titers
(98). However, although these studies provide a proof of concept
for peptide vaccination for therapeutic use in HCV infection, the
improvements are only minor.
For a preventive peptide vaccine, there are different neces-
sities. First of all, it should target conserved sequences, which
could lead to a universal vaccine. Possible target proteins have
been identified for viruses such as HIV, HCV, and influenza (44–
46). Especially in influenza vaccine development, the threat for
a new pandemic to occur has boosted research on the develop-
ment of such a universal vaccine. The research of Tan et al., in
which they make use of lipopeptides directed to conserved com-
ponents, is one of many examples of strategies that are currently
developed and have proven themselves in mouse models but not
yet in human systems (53). Other vaccination strategies, currently
in development, include the use of virus-like particles in combi-
nation with an antibody-inducing influenza protein such as the
relatively conserved M2e protein or lipopeptide in combination
with liposomes (92, 99, 100). A recent advancement is that there
are some peptide-based vaccines against influenza virus infection
in Phase I clinical trials, that are able to induce vaccine-specific
cellular immunity (101, 102).
CONSIDERATIONS FOR PEPTIDE VACCINE DEVELOPMENT
When designing peptide-based vaccines, there are several things
to take into consideration, such as virus traits, side effects, loca-
tion of the response, and traits of the host (see Table 2 for an
overview). First, the objective of vaccination should be taken into
consideration. Vaccines can be largely divided into therapeutic
and preventive. Preventive peptide-based vaccines should elicit a
robust memory T cell response, since vaccine-induced T cells need
to respond rapidly after infection to clear the virus before it causes
illness or at least to limit disease burden. In the case of therapeutic
vaccination to chronic infections, the response should be vigorous
and elongated and a rapid response is of less importance. Both
for therapeutic and preventive vaccines, eliciting this response at
the required location is of great value. Peptide-based vaccines for
respiratory viruses, for example, might be more effective when
administered intranasally, since lung resident immune cells might
then be primed more easily (103). However, changing the route of
administration is not always sufficient and then adjuvants in the
form of delivery vehicles might aid in transporting vaccine com-
ponents to the right location in order to elicit an efficient T cell
response.
Although inducing T cell responses is very important in protec-
tion against many pathogens, there are also indications that these
www.frontiersin.org April 2014 | Volume 5 | Article 171 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rosendahl Huber et al. Peptide vaccination for viral infections
Table 2 | Design of a peptide-based vaccine for preventive or
therapeutic use.
Factor Preventive Therapeutic
Route of
immunization
Unimportant Wanted
Time to develop response Virus present on certain
location
Existing
response
Unimportant Important
Inducing new response Boost existing T cell
response
Rapid effector
response
Wanted Unimportant
Preventing or limiting disease Clearance in the end
Inducing
memory
Wanted Unimportant
T cells available when infected Recall response not
necessary
Side effects Unwanted Unimportant
Reason to withdraw vaccine Accepted for certain
diseases
There are several factors to take into consideration when designing peptide-based
vaccines, such as location of the response, type of response to be induced, and
side effects. The contribution of these factors in the design of preventive versus
therapeutic vaccines are summarized in the table.
T cell responses cause harm. This is illustrated for influenza infec-
tion, in which a high number of virus-specific CD4+ T cells in
patients infected with pandemic influenza A virus from 2009, cor-
related with more severe illness (104). In the case of HCV infection,
a broad and specific T cell response is able to control virus infec-
tion (105). However, during chronic viral infection, liver damage
occurs, which is assumed to be immune-mediated. In a study by
Maini et al., a high number of antigen-specific T cells in the blood
did not correlate with the amount of liver damage as measured
by alanine transaminase (ALT, indicative of liver damage). In con-
trast, Feuth et al. show a direct correlation between the number
of differentiated CD8+ T cells, which contain high perforin levels,
and liver fibrosis measured by fibroscan elastography (106). Since a
large number of T cells are detected in the liver of patients with liver
damage, damage has been proposed to be caused by the recruit-
ment of non-virus-specific T cells (107). Although in humans the
mechanism by which immunopathology develops is not clear, it is
important to bear in mind that an exaggerated T cell response to
infection or vaccination may lead to unwanted immune-mediated
damage. Therefore, vaccine-induced T cell responses should be
effective against the virus, without eliciting major side effects.
Traits of the host also influence the effectiveness of a vaccine.
Therefore, it is important to consider the target group for vaccina-
tion. During a human’s lifetime, the immune system will change
continuously. Vaccination in early childhood can have a major
impact on the immune response in later years as described by
Bodewes et al. in which it was shown that annual vaccination
with a seasonal inactivated subunit influenza vaccination ham-
pers the development of influenza-specific CD8+ T cells (108).
To underline this finding, Hoft et al. compared a live attenuated
influenza vaccine (LAIV) with a trivalent inactivated influenza
vaccine (TIV) in young children, and found that only LAIV
induced diverse T cells responses (109). Both studies show that the
type of vaccination is of crucial importance both for the induction
of T cell responses directly after vaccination and to T cell responses
to the pathogen later in life. That age of the target group should
be an important factor in the design of a vaccine is further exem-
plified by a study on influenza vaccination in elderly. In this study,
antibody titers did not predict who developed influenza related
illness, while T cell responses did (110). This effect is supported by
evidence that T cell responses wane in elderly individuals. Several
studies have shown that T cells from elderly individuals have a
more differentiated phenotype characterized by the lack of CD27
expression and upregulation of CD57. The presence of CD57 on
CD8+ T cells is associated with decreased proliferation of CD8+ T
cells. Lack of markers, such as CD28, leads to an increased Th1
skewed response, which may contribute to decreased antibody
titers in elderly individuals (111–113). Not only T cell responses
wane, but also antibody responses diminish (114). Therefore, age
of the target group should be an important consideration for the
development of vaccines.
PROSPECTS FOR PEPTIDE VACCINATION
Taken together, severity of side effects is an important factor in the
consideration of vaccine application. The licensed HPV peptide-
based vaccine contains Montanide, which is a strong adjuvant
causing lesions at the site of infection (87). For the therapeutic
HPV vaccine, these side effects were deemed acceptable; however,
they were one of the reasons to abort studies with Montanide-
containing vaccines for HIV and malaria (88, 89). Consequently,
before this peptide-based vaccine concept can be widely imple-
mented, Montanide has to be replaced by another adjuvant. How-
ever, to elicit a response to these long overlapping peptides, a
strong adjuvant is necessary. Therefore, the challenge is to increase
immunogenicity of conserved targets for which T cells are available
(43–45). A promising self-adjuvanting approach, which induces a
broad response, is using multiple antigenic peptide (MAP). This
approach was implemented in HCV patients by El-Awady et al.
and was capable of inducing both antibody and T cell responses
in two thirds of the patients (98, 115).
The ultimate goal in protection against rapidly mutating viruses
such as influenza, is to develop a universal vaccine, protecting
against currently circulating influenza strains, but also able to
cross-protect against newly emerging strains and thereby prevent-
ing future pandemics. These preventive peptide-based vaccines
should elicit a robust memory T cell response, since vaccine-
induced T cells need to respond rapidly after infection to clear
the virus before it causes illness. To induce a pool of both memory
CD4+ T cells and memory CD8+ T cells, efficient priming of naïve
T cells is required. Professional APCs need to present the antigen
to both CD4+ and CD8+ T cells. As most vaccines induce T cells
via extracellular routing, cross priming is of specific significance
since it enables the presentation of extracellular-derived particles
on MHC class I molecules. Targeting the more conserved parts
of the virus by designing peptide-based vaccines, is a promising
concept in the design of these preventive vaccines. Especially in
influenza vaccine development, there are several examples of pilot
vaccines directed to more conserved parts of the virus that should
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cross-protect to heterologous viruses. These vaccines often contain
both antibody and T cell inducing components (116, 117).
Concluding, in addition to antibody responses, T cell responses
are of major importance in limiting and clearing virus infections.
Effective therapeutic and preventive vaccines should therefore be
able to induce both antibody and T cell responses. Peptide-based
vaccines can meet these demands and induce both antibody and T
cell responses. Furthermore, because peptides are synthetic, they
are safe and relatively easy to produce. Currently, several peptide-
based vaccines, for viruses such as EBV, HBV, and influenza virus,
are evaluated in clinical trials (101). Hurdles to overcome are
choosing the right target epitopes and choosing adjuvants that
improve immunogenicity of these epitopes and steer the immune
response in the desired direction. Adjuvants for peptide-based
vaccines should target antigen to DCs, or other APCs capable of
cross-presentation, and provide stimuli to ensure efficient presen-
tation of the antigen. In addition, an overstimulation resulting in
immunopathology should be avoided. Providing, these criteria are
met, the future of peptide-based vaccines is very promising.
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